pharmaphorum February 15, 2024
Phil Taylor

People at risk of losing a finger or toe to frostbite now have the first FDA-approved treatment that could prevent a life-changing amputation.

The US regulator has cleared Aurlumyn (iloprost) injection from CiVi Biopharma subsidiary Eicos Sciences as a treatment for severe frostbite, caused by prolonged exposure to extreme cold, after a priority review.

The incidence of severe frostbite injury in the US is estimated at 0.8 out of 100,000 people, meaning that there are approximately 2,800 cases a year, with cases disproportionately affecting the homeless in urban areas, but also seen in military personnel, industrial workers, and people who engage in outdoor sports like mountaineering, skiing, and hiking.

There are thought to be around 14,000 cases of frostbite overall...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article